Cargando…

Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features

OBJECTIVE: To evaluate the efficacy of the PD-1 inhibitor camrelizumab plus chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) and the prognostic differences of patients with different PET/CT features. METHODS: Between December 2018 and October 2020, 100 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Jinhai, Li, Chunying, Han, Yu, Xing, Yu, Zhan, Yingying, Zuo, Chao, Ren, Xinyue, Xing, Rongge, Zhang, Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975645/ https://www.ncbi.nlm.nih.gov/pubmed/35368889 http://dx.doi.org/10.1155/2022/9942918

Ejemplares similares

Prognostic Value of (18)F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis
por: Liu, Jing, et al.
Publicado: (2016)

Epithelioid hemangioendothelioma in the thorax: Clinicopathologic, CT, PET, and prognostic features
por: Woo, Jung Han, et al.
Publicado: (2016)

Case report of (18)F-FDG PET/CT features of hypoglycemic encephalopathy
por: Shen, Xun-Ze, et al.
Publicado: (2023)

Combining (18)F‐FDG PET/CT and Serum Lactate Dehydrogenase for Prognostic Evaluation of Small Cell Lung Cancer
por: Lin, Xiaoping, et al.
Publicado: (2020)

Prognostic Significance of Metabolic Parameters and Textural Features on (18)F-FDG PET/CT in Invasive Ductal Carcinoma of Breast
por: Chang, Chin-Chuan, et al.
Publicado: (2019)

The prognostic value of PET and PET/CT in cervical cancer
por: Grigsby, Perry W.
Publicado: (2008)

The prognostic value of PET and PET/CT in cervical cancer
por: Koh, Dow-Mu, et al.
Publicado: (2008)

Prognostic Evaluation Based on Dual-Time (18)F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic Cancer Treated by Stereotactic Body Radiation Therapy
por: Wang, Fei, et al.
Publicado: (2022)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Case report: Camrelizumab associated with central retinal vein occlusion
por: Zhan, Yixiang, et al.
Publicado: (2022)

Respiration-Averaged CT for Attenuation Correction of PET Images – Impact on PET Texture Features in Non-Small Cell Lung Cancer Patients
por: Cheng, Nai-Ming, et al.
Publicado: (2016)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
por: Yu, Yi, et al.
Publicado: (2021)

Pleomorphic carcinoma of the lung: Prognostic models of semantic, radiomics and combined features from CT and PET/CT in 85 patients
por: Kim, Chohee, et al.
Publicado: (2021)

PET/CT in the Staging of the Non-Small-Cell Lung Cancer
por: Chao, Fangfang, et al.
Publicado: (2012)

Immune-Related Colitis Induced by Camrelizumab: A Case Report
por: Cheng, Sheng, et al.
Publicado: (2023)

Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
por: Ren, Yanqiao, et al.
Publicado: (2022)

Comparison of Conventional and Radiomic Features between (18)F-FBPA PET/CT and PET/MR
por: Liao, Chien-Yi, et al.
Publicado: (2021)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Novel long noncoding RNA GACAT3 promotes colorectal cancer cell proliferation, invasion, and migration through miR-149
por: Zhou, Weiwei, et al.
Publicado: (2018)

Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma
por: Lim, Chae Hong, et al.
Publicado: (2021)

Camrelizumab for cancers in patients living with HIV: one-single center experience
por: Wu, Menghua, et al.
Publicado: (2023)

Immune-related adverse events as independent prognostic factors for camrelizumab in patients with esophageal squamous cell carcinoma: a retrospective cohort study
por: Zhao, Ya-Nan, et al.
Publicado: (2023)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2021)

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
por: Huang, Yahan, et al.
Publicado: (2022)

Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Ye, Wei, et al.
Publicado: (2022)

Metabolic tumor volume and conformal radiotherapy based on prognostic PET/CT for treatment of nasopharyngeal carcinoma
por: Fei, Zhaodong, et al.
Publicado: (2019)

New PET/CT Features for the Evaluation of Tumor Response
por: Lu, Wei
Publicado: (2013)

Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
por: Lin, Jieheng, et al.
Publicado: (2021)

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
por: Chen, Yao, et al.
Publicado: (2020)

Solitary Pulmonary Capillary Hemangioma: CT and PET-CT Features with Clinicopathologic Correlation
por: Kim, Min Ju, et al.
Publicado: (2022)

Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

Prognostic value of (18)F-FDG PET/CT metabolic parameters in small cell lung cancer
por: Choi, Eun Kyoung, et al.
Publicado: (2019)

Influencing Factors and Prognostic Value of (18)F-FDG PET/CT Metabolic and Volumetric Parameters in Non-Small Cell Lung Cancer
por: Zhang, Lixia, et al.
Publicado: (2021)

A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
por: Huang, Julu, et al.
Publicado: (2023)

Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Different Prognostic Values of Dual-Time-Point FDG PET/CT Imaging Features According to Treatment Modality in Patients with Non-Small Cell Lung Cancer
por: Jang, Su Jin, et al.
Publicado: (2022)

Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature
por: Tan, You-Wen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4n3svm1pt0t1hvaeivgvno2s2q